DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe
Filed with ASX · · 5 pages · English
Story so far
Earlier from Dimerix
- Pause in Trading
- First Approvals Received for Start of Phase 3 FSGS Trial
- Phase 3 DMX-200 COVID-19 Study Expands into Australia
- Dimerix Closes SPP Oversubscribed
- DMX-200 CLARITY COVID-19 Study Approval in India
Later from Dimerix
- Ethics Approval in Australia for Phase 3 COVID-19 Study
- Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
- First Regulatory Approval in Europe for DMX-200 FSGS Study
- Half-Year Financial Report & Appendix 4D - 31 December 2021
- DSMB Change to REMAP-CAP COVID-19 Study
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix